St. Albans, United Kingdom

Sean Thomas Flynn


Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 49(Granted Patents)


Location History:

  • Hertfordshire, GB (1991)
  • St. Albans, GB (1993)
  • St Albans, GB (2002)

Company Filing History:


Years Active: 1991-2002

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Sean Thomas Flynn

Introduction: Sean Thomas Flynn, an accomplished inventor based in St. Albans, Great Britain, has made significant strides in the field of chemical innovations. With a total of three patents to his name, Flynn's work primarily focuses on the development of compounds with therapeutic benefits.

Latest Patents: One of Flynn's recent patents, titled "Bicyclic compounds as ligands for 5-HT1 receptors," introduces phenylpyridone derivatives that exhibit bronchodilator and anti-allergic activities. A specific compound highlighted in this invention is 6-(2-propoxyphenyl)-1,2-dihydro-2-oxopyridine-3-carboxamide, showcasing his innovative approach to medicinal chemistry.

Career Highlights: Throughout his career, Flynn has worked with renowned organizations, including Smith Kline & French Laboratories Limited and SmithKline Beecham Corporation. His experiences in these companies have contributed enormously to his expertise and understanding of chemical innovation.

Collaborations: Flynn has collaborated with notable colleagues such as William J. Coates and Derek A. Rawlings. These partnerships have likely fueled the creativity and scientific rigor behind his inventions, further enhancing his impact in the pharmaceutical industry.

Conclusion: Sean Thomas Flynn stands out as a prominent figure in chemical inventions, particularly in developing compounds that offer therapeutic benefits. His patented innovations and collaborations with esteemed colleagues reflect the importance of teamwork and creativity in advancing science. Flynn's contributions continue to be invaluable in the quest for effective treatments and innovations in the biomedical sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…